Agios Pharmaceuticals
Stock Forecast, Prediction & Price Target
Agios Pharmaceuticals (AGIO) stock Price Target by analysts
$53.5
Potential upside: 47.70%
Agios Pharmaceuticals price prediction
What is Agios Pharmaceuticals stock analysts` prediction?
Agios Pharmaceuticals stock forecast: Based on 2 Wall Street analysts` predicted price targets for Agios Pharmaceuticals in the last 3 months, the avarage price target is $53.5, with a high forecast of $NaN. The average price target represents a 47.70% change from the last price of $36.22.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Agios Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Agios Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Danielle Brill Raymond James | 0% 0/1 | 11 months ago | $51 40.80% upside | $44.43 | StreetInsider | Previous targets (0) |
Andrew Berens Leerink Partners | 0% 0/1 | about 1 year ago | $56 54.61% upside | $45.61 | StreetInsider | Previous targets (0) |
Chris Raymond Raymond James | 0% 0/3 | about 1 year ago | $56 54.61% upside | $44.05 | StreetInsider | Previous targets (2) |
Chris Raymond Raymond James | 0% 0/3 | over 1 year ago | $55 51.84% upside | $43.42 | StreetInsider | Previous targets (2) |
Gregory Renza RBC Capital | 0% 0/1 | over 1 year ago | $53 46.32% upside | $44.26 | TheFly | Previous targets (0) |
Chris Raymond Raymond James | 0% 0/3 | over 1 year ago | $45 24.24% upside | $38.39 | StreetInsider | Previous targets (2) |
Unknown Piper Sandler | N/A | over 2 years ago | $41 13.19% upside | $30.18 | Benzinga | N/A |
Unknown J.P. Morgan | N/A | almost 3 years ago | $33 -8.89% downside | $29.46 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | almost 3 years ago | $32 -11.65% downside | $27.13 | Benzinga | N/A |
Peter Lawson Barclays | 0% 0/1 | over 4 years ago | $70 93.26% upside | $55.8 | TheFly | Previous targets (0) |
Agios Pharmaceuticals Financial Estimates
Agios Pharmaceuticals Revenue Estimates
Agios Pharmaceuticals EBITDA Estimates
Agios Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $14.24M 0% | $26.82M 88.36% | Avg: $124.92M Low: $80.17M High: $202.02M avg. 365.75% | Avg: $220.99M Low: $139.37M High: $388.44M avg. 76.89% | Avg: $375.64M Low: $236.90M High: $660.26M avg. 69.97% | Avg: $562.84M Low: $354.97M High: $989.31M avg. 49.83% |
Net Income
% change YoY
| $1.60B N/A | $-74.55M -104.64% | $-352.08M -372.25% | Avg: $-342.08M Low: $-382.32M High: $-174.74M avg. 2.84% | Avg: $-286.18M Low: $-399.57M High: $-72.90M avg. 16.34% | Avg: $-77.13M Low: $-153.11M High: $-40.09M avg. 73.04% | Avg: $79.99M Low: $41.59M High: $158.79M avg. 203.71% |
EBITDA
% change YoY
| $-385.05M N/A | $-526.75M -36.79% | $-384.86M 26.93% | Avg: $-74.95M Low: $-121.21M High: $-48.10M avg. 80.52% | Avg: $-132.59M Low: $-233.06M High: $-83.62M avg. -76.89% | Avg: $-225.38M Low: $-396.16M High: $-142.14M avg. -69.97% | Avg: $-337.70M Low: $-593.59M High: $-212.98M avg. -49.83% |
EPS
% change YoY
| $26.55 N/A | -$1.36 -105.12% | -$6.33 -365.44% | Avg: -$5.62 Low: -$6.87 High: -$3.14 avg. 11.20% | Avg: -$4.5 Low: -$7.18 High: -$1.31 avg. 19.90% | Avg: -$1.39 Low: -$2.75 High: -$0.72 avg. 69.21% | Avg: $1.44 Low: $0.75 High: $2.85 avg. 203.71% |
Operating Expenses
% change YoY
| $378.41M N/A | $401.58M 6.12% | $408.80M 1.79% | Avg: $396.47M Low: $254.45M High: $641.15M avg. -3.01% | Avg: $701.34M Low: $442.32M High: $1.23B avg. 76.89% | Avg: $1.19B Low: $751.85M High: $2.09B avg. 69.97% | Avg: $1.78B Low: $1.12B High: $3.13B avg. 49.83% |
FAQ
What is Agios Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 73.98% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is -382.32M, average is -342.08M and high is -174.74M.
What is Agios Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 140.61% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $80.17M, average is $124.92M and high is $202.02M.
What is Agios Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 76.00% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is -$6.87, average is -$5.62 and high is $-3.14.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Agios Pharmaceuticals stock. The most successful analyst is Danielle Brill.